GlassScriptPhysician profile
David W Heine
NPI 1750397899
$2,582.87
in general payments reported to CMS, 2019-2025
24 companies · $561 in 2025
The $561 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $420 · 2021: $175 · 2022: $121 · 2023: $312 · 2024: $437 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,309.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $507.63 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $469.78 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $317.07 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $254.50 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $200.14 | 2019-2023 | |
| Astellas Pharma US INC | $110.24 | 2019-2024 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $98.13 | 2019-2021 | |
| Boston Scientific Corporation | $94.94 | 2021-2025 | Watchman Access System, General - Pain Management |
| Abbvie INC. | $73.46 | 2019-2025 | |
| Amgen INC. | $55.48 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.02 | 2024-2025 | Jardiance |
| Exact Sciences Corporation | $46.95 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $45.62 | 2024-2025 | Rexulti |
| Amarin Pharma, INC. | $43.41 | 2019 | |
| Abbott Laboratories | $42.82 | 2025 | Freestyle Libre |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $39.85 | 2019-2021 | |
| Dexcom, INC. | $20.07 | 2024 | Dexcom G6 Transmitter |
| Cardiovascular Systems INC. | $19.82 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $18.21 | 2019 | |
| Medtronic, INC. | $17.83 | 2024 | Closurefast |
| Hikma Pharmaceuticals USA | $15.92 | 2020 | |
| Idorsia Pharmaceuticals US INC | $15.65 | 2024 | Quviviq |
| Allergan, INC. | $14.99 | 2019 | |
| Ibsa Pharma INC. | $13.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Heine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.